Back to top
more

Cempra, Inc. (CEMP)

(Delayed Data from NSDQ)

$2.33 USD

2.33
511,620

+0.03 (1.09%)

Updated Nov 3, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Melinta Therapeutics, Inc. [CEMP]

Reports for Purchase

Showing records 61 - 80 ( 89 total )

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 61

08/02/2015

Industry Report

Pages: 2

Biotechnology: 2H15 Catalysts For Key Stocks From Our Research Universe

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 62

07/30/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 63

07/30/2015

Company Report

Pages: 9

Pipeline in a Product Continues to Steam Ahead

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 64

07/27/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 65

07/27/2015

Daily Note

Pages: 5

2Q15 Preview, All Eyes on Solitaire IV Readout

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 66

07/22/2015

Industry Report

Pages: 15

Antibiotics Update: Data Catalysts Approaching

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 50.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 67

07/20/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 68

07/20/2015

Company Report

Pages: 9

Solithromycin Positioned to Eclipse Macrolides in COPD, Target to $56

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 69

07/14/2015

Company Report

Pages: 12

Highlights from Management/Investor Meetings, Adding to Focus List

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 70

07/14/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 71

07/08/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 72

07/08/2015

Company Report

Pages: 5

Pricing Strategy Key to Robust Commercial Launch

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 73

06/22/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 74

06/21/2015

Daily Note

Pages: 5

Solitaire-IV Readout (4Q15) Should Position Soli'' as First-Choice Therapy

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 75

05/21/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 76

05/21/2015

Company Report

Pages: 11

Solithromycin''s A Potential Blockbuster in the Making

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 77

05/01/2015

Company Report

Pages: 2

Cempra reported first quarter results

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 78

04/07/2015

Industry Report

Pages: 2

Healthcare -Biotechnology: Catalyst Tracker Through Mid-15

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 79

03/30/2015

Industry Report

Pages: 2

Healthcare: Biotechnology: Its Yogi Berra All Over Again

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 80

03/03/2015

Company Report

Pages: 4

Transferring Coverage

Provider: Roth Capital Partners, Inc.

Analyst: MARTIN J

Price: 10.00

Research Provided by a Third Party